



ABN 11 124 426 339

Level 3, 2-4 Ross Place, South Melbourne, VIC 3205

P +61 (3) 9673 9690 F +61 (3) 9673 9699

[www.purifloh.com](http://www.purifloh.com) E [corporate@purifloh.com](mailto:corporate@purifloh.com)

30 October 2020

ASX Announcements

4<sup>th</sup> Floor

20 Bridge Street

Sydney, NSW, 2000

## QUARTERLY OPERATIONS UPDATE

PurifloH Limited ("PurifloH", "PO3" or "Company") is pleased to provide an update of activities over the last quarter to 30 September, 2020 as well as advising of further scientific appointments.

## TECHNICAL APPOINTMENTS

The Company has finalised the engagement of Dr. Alex Sava to work with Mr Jon Evans and to focus on technical elements of commercial execution.

Dr. Sava was a co-founder, co-inventor and Non-Executive Director of Nanosonics Pty Ltd from November 2000 until prior to its listing on ASX on May 2007 as Nanosonics Limited (ASX:NAN).

From October 2016 till December 2019 Dr. Sava also served as a non-executive director of Aeris Environmental Ltd (ASX: AEI).

Dr. Sava is highly regarded in the scientific and investment communities for his broad expertise and proven track record of successful commercial execution of scientific innovation similar to that of PO3. Commercialising his inventions in many international markets has provided Dr Sava with strong regulatory and commercial experience that will be of specific relevance to the Company.

Dr. Sava holds an M.Sc. in Chemical Engineering and a Ph.D. in Physical Chemistry from the Ukrainian Academy of Science. His credentials include over 35 years experience in microbiology, chemistry and biochemistry. Dr Sava holds over 100 international patents and has authored over 50 scientific articles. He will work closely with PurifloH Board Member and principal PO3 technology inventor, Professor Pravansu Mohanty of Somnio Global in Detroit.

Dr. Sava has achieved commercial execution with the following inventions:

- Aerosol hydrogen peroxide disinfection process ('nanonebulant'), the core technology of Nanosonics Limited (ASX:NAN);
- Fast and economical assay of biological and chemical contaminants in hospitals, hotels and residential premises;
- World-first pathogen-disinfecting technologies based on symbiotic mixtures of natural enzymes with biocides. Achieving manyfold reduction in concentration of toxic biocides without compromising biocidal efficacies – one of friendliest to the environment disinfection processes available to hospitals worldwide.

Dr. Sava commented that: *"I am excited to join the team having had the opportunity to undertake a thorough due diligence of this exciting technology as it engages with various sectors of industry. I have taken the opportunity to spend time in the facilities of Somnio Global in Detroit. Its capabilities are of enormous benefit to PurifloH."*

*I have been particularly impressed by PuriflOH's process capability to kill both bacterial endospores and MS2 bacteriophage – an 'overly conservative' surrogate for validating broad virucidal efficacy. I am confident that any process capable of destroying > 99.99% of MS2 bacteriophage and bacterial endospores in a single pass could easily destroy any airborne virus. This will be a focus of the Company in the immediate future."*

The Company is also pleased to advise the appointment of Mr. Vigneswaran Appia in its Melbourne office who will support and complement Dr. Sava.

Mr. Appia is a co-author of the Free Radical Generator patent – one of the PO3 's core patents - and was previously a Project Leader at Somnio Global in Detroit, Michigan, working on application development and product development of the core technology.

He holds a Masters degree in Mechanical Engineering from Arizona State University and now resides in Melbourne. He brings his intimate knowledge and experience with the core technology, as well as a strong level of contact with the scientific team in Detroit with whom he closely worked. This will provide significant on-ground capability for the commercialization activities commencing in Australia.

## **MARKET DEVELOPMENT, INDUSTRIAL DESIGN and MANUFACTURING**

The recent appointment of Mr. Jon Evans to the Board and his work with the Company over the last two months indicates an increase in activity within Australia. This is further supported by the engagement of Dr. Sava and Mr. Appia as noted above. It is proposed that this activity will run in parallel, and be supported by, activity at Somnio Global in Detroit.

Mr. Evans in turn has introduced Mr. Will Siganto, a Mechanical Engineer and Fellow of the Institute of Engineers Australia, who has over 25 years experience in the HVAC contracting and servicing industry in Australia, Singapore and Dubai has been engaged to oversee the manufacturing process for the purifiers.

This move towards manufacturing arises as Mr. Evans and Mr. Siganto have been working with a number of industry groups where interest in access to the air purifier has been strong. Consequently system prototypes have arrived in Australia to assist ongoing proof of concept within Australia and to aid industrial design finalisation.

The Company also plans to utilise the prototypes to test its efficacy to destroy Covid-19 at a suitable and independent Good Practice Laboratory in Australia. The Company has previously released results (ASX: 17 April 2018 "Aerosol Test Results") which confirmed the ability of the Company's prototype device to kill microbes selected for being the most resistant representative airborne species in their class - spores, bacteria, fungi and viruses. To that end it will approach these tests with confidence.

## **FUNDING**

The Company has received an offer of a financing facility capable of immediate drawdown from its major shareholder, Dilato Holdings Pty Ltd. This drawdown facility is in the sum of A\$1M which, with current cash at bank, will more than cover requirements to prove 2 quarters of cash. The facility is available to draw down on an as needed basis with a flat interest rate of 10% to be paid on outstanding balances. Dilato has in the recent past provided similar facilities to assist the Company, most notably the \$2M facility provided in 2014 (ASX: "Finance Proposal" 30/5/2014) which was ended by mutual agreement on 31 December 2019. The ability to draw down on this loan will be available through to 31 December 2021.

**This ASX report is authorized for release by Mr. Simon Lill (Director)**  
**For further information:**

**Simon Lill (Director)**  
**Australia**  
**+613 9673 9673**

**Steve Annear**  
**USA (Detroit)**  
**+1 248 567 9616**